VICTORY project: impact of complex pharmacotherapy on compensation of patients with type 2 diabetes mellitus

Česká verzia

Authors: Martin Šatný; Michal Vrablík
Authors place of work: Centrum preventivní kardiologie, III. interní klinika – endokrinologie a metabolismu 1. LF UK a VFN v Praze
Published in the journal: AtheroRev 2023; 8(3): 153-164
Category: Clinical Studies

Summary

Type 2 diabetes (T2D) is a major medical problem, as it is a disease of increasing prevalence with a range of microvascular and macrovascular complications that require costly treatment. The VICTORY project was designed as a non-interventional prospective multicenter trial to investigate the efficacy and safety of intensive complex therapy in patients with expressed insulin resistance (IR) or T2D in real clinical practice. The main aim of this project was to characterize the cohort in detail, to identify possible explanations for the lack of control in the patients studied and, last but not least, to analyze the impact of the initial intervention over a time horizon of 6–12 months. The results of the VICTORY project are an important mirror of common clinical practice, which shows unsatisfactory control of both T2D and associated comorbidities. However, the positive message remains that if intervention is thought of, even in a relatively short timeframe (6–12 months) – through comprehensive patient management – better compensation can be achieved. The choice of appropriate antidiabetic, antihypertensive or lipid-lowering treatment, hand in hand with regimen measures and diet modification, can have a profound effect on morbidity and mortality in diabetics.

Keywords:

arterial hypertension – cardiovascular risk – dyslipidemia – pharmacotherapy – type 2 diabetes

Zdroje

Riddle MC, Herman WH. The Cost of Diabetes Care – An Elephant in the Room. Diabetes Care 2018; 41(5): 929–932. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0012>.
Lee SH, Park SY, Choi CS. Insulin Resistance: From Mechanisms to Therapeutic Strategies. Diabetes Metab J 2022; 46(1): 15–37. Dostupné z DOI: <http://dx.doi.org/10.4093/dmj.2021.0280>.
Gaede P, Oellgaard J, Carstensen B et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia 2016; 59(11): 2298–2307. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–016–4065–6>.
Šatný M, Tůmová E, Vrablík M. LIPIcontrol: daří se zlepšovat úroveň kontroly hlavních rizikových faktorů kardiovaskulárních onemocnění v každodenní praxi?. Hypertenze KV Prevence 2018; 7(1): 15–21.
Šatný M, Tůmová E, Vrablík M. Srovnání profilu a léčby pacientů s nekontrolovanou arteriální hypertenzí a/nebo dyslipidemií v péči specialistů a v primární péči v Česku: srovnání výsledků studie LipitenCliDec 1 a LipitenCliDec 2. AtheroRev 2021; 6(3): 154–162.
Ray KK, Molemans B, Schoonen WM et al. DA VINCI study. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol 2021; 28(11): 1279–1289. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjpc/zwaa047>.
Kotseva K. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovasc Diagn Ther 2017; 7(6): 633–639. Dostupné z DOI: <http://dx.doi.org//10.21037/cdt.2017.04.06>.
Visseren FL, Mach F, Smulders YM et al. [ESC National Cardiac Societies; ESC Scientific Document Group]. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; 42(34): 3227–3337. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehab484>.
Holman RR, Retnakaran R, Farmer A et al. PROactive study. Lancet 2006; 367(9504): 25–26. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(06)67914–2>.
Kernan WN, Viscoli CM, Furie KL et al. [IRIS Trial Investigators]. Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. N Engl J Med 2016; 374(14): 1321–1331. Dostupné z DOI: <http://do.doi.org/10.1056/NEJMoa1506930>.
Mancia G, Kreutz R, Brunström M et al. [Authors/Task Force Members]. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens 2023; Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0000000000003480>.
Emdin CA, Rahimi K, Neal B et al. Blood pressure lowering in type 2 diabetes: a systematic review and metaanalysis. JAMA 2015; 313(6): 603–615. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.18574>.
Dahlöf B, Sever PS, Poulter NR et al. [ASCOT Investigators]. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895–906. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67185–1>.
Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst 2000; 1(1): 18–20. Dostupné z DOI: <http://dx.doi.org/10.3317/jraas.2000.002>.
Bosch J, Lonn E, Pogue J et al. [HOPE/HOPE-TOO Study Investigators]. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339–1346. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.105.548461>.
Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab Res Rev 2002; 18(Suppl 3): S82-S85. Dostupné z DOI: <http://dx.doi.org/10.1002/dmrr.285>.
ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358(24): 2560–2572. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa0802987>.
Kearney PM, Blackwell L, Collins R et al. [Treatment Trialists‘ (CTT) Collaborators]. Efficacy of cholesterollowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a metaanalysis. Lancet 2008; 371(9607): 117–125. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)60104-X>.
Cannon CP, Braunwald E, McCabe CH et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15): 1495–1504. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa040583>.
Giugliano RP, Cannon CP, Blazing MA et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation 2018; 137(15): 1571–1582. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.117.030950.>.
Maki KC, Guyton JR, Orringer CE et al. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. J Clin Lipidol 2016; 10(4): 905–914. Dostupné z DOI: <http://dx.doi.org10.1016/j.jacl.2016.03.008>.
Keech A, Simes RJ, Barter P et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366(9500): 1849–1861. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(05)67667–2>.